shepherdin

12/28/2006 - "The compound is selected to bind the Hsp90 N-terminal domain, mimicking the chemical and conformational properties of the recently described peptidic antagonist of the survivin-Hsp90 complex, shepherdin [Plescia et al. Cancer Cell 2005, 7, 457-468]. "
08/02/2006 - "Shepherdin[79-83] abolished growth of AML xenograft tumors (mean of control group = 1698 mm3 and mean of treated group = 232 mm3; difference = 1466 mm3, 95% confidence interval = 505.8 to 2426; P = .008) without systemic or organ toxicity and inhibited Hsp90 function in vivo. "
08/02/2006 - "Effects of shepherdin on tumor growth were evaluated in AML xenograft tumors in mice (n = 6). "
05/01/2005 - "Systemic administration of shepherdin in vivo is well tolerated, and inhibits human tumor growth in mice without toxicity. "
05/25/2016 - "In RB cells, anti-tumor effects were detected with 0.42 μg/ml of shepherdin at 4 h s of serum starvation. "

08/02/2006 - "We investigated Hsp90 as a therapeutic target for acute myeloid leukemia (AML) by use of the Hsp90 inhibitor shepherdin (a novel peptidyl antagonist of the interaction between Hsp90 and survivin, which is a regulator of cell proliferation and cell viability in cancer). "

06/28/2009 - "Conversely, the inhibition of TRAP1 activity by TRAP1 ATPase antagonist, shepherdin, increased the sensitivity to oxaliplatin and irinotecan in colorectal carcinoma cells resistant to the single agents. "

05/25/2016 - "In RB cells, anti-tumor effects were detected with 0.42 μg/ml of shepherdin at 4 h s of serum starvation. "
05/25/2016 - "Serum starvation induced HSP90 whose interactions with Survivin were specifically inhibited by shepherdin. "

05/25/2016 - "Targeting HSP90/Survivin using a cell permeable structure based peptido-mimetic shepherdin in retinoblastoma."